ROME Therapeutics
ROME Therapeutics is dedicated to illuminating the dark genome to pioneer new therapeutic approaches for serious diseases such as cancer and autoimmune disorders. They focus on the vast, underexplored regions of DNA known as the dark genome, which contains repetitive elements that can be activated in diseased cells. Their mission is to leverage insights from this genome to develop breakthrough treatments, particularly targeting elements like LINE-1 reverse transcriptase that are linked to disease processes.
Industries
Nr. of Employees
small (1-50)
ROME Therapeutics
Patents
Products
LINE-1 reverse transcriptase inhibitor (development candidate)
A small-molecule inhibitor targeting LINE-1-derived reverse transcriptase activity intended to suppress repeat-induced Type I interferon signaling and other disease-associated processes; nominated development candidate being advanced toward clinical development for autoimmune and neurodegenerative indications.
Annotated repeat database (mapping reference)
A curated, high-resolution database of annotated repetitive genomic elements intended to serve as a reference for expression quantification and target discovery.
Machine learning repeat expression quantification tool
A computational tool that uses machine learning to quantify expression of active repeats and identify disease-associated repeat activities.
LINE-1 reverse transcriptase inhibitor (development candidate)
A small-molecule inhibitor targeting LINE-1-derived reverse transcriptase activity intended to suppress repeat-induced Type I interferon signaling and other disease-associated processes; nominated development candidate being advanced toward clinical development for autoimmune and neurodegenerative indications.
Annotated repeat database (mapping reference)
A curated, high-resolution database of annotated repetitive genomic elements intended to serve as a reference for expression quantification and target discovery.
Machine learning repeat expression quantification tool
A computational tool that uses machine learning to quantify expression of active repeats and identify disease-associated repeat activities.
Services
A unified set of genomic analysis tools for high-resolution mapping of repetitive elements and machine learning-based quantification of their expression to support target identification, indication selection, biomarker discovery and clinical study design.
Collaborative arrangements to apply expertise in repeat biology, structural biology, and data science to joint discovery or translational projects.
A unified set of genomic analysis tools for high-resolution mapping of repetitive elements and machine learning-based quantification of their expression to support target identification, indication selection, biomarker discovery and clinical study design.
Collaborative arrangements to apply expertise in repeat biology, structural biology, and data science to joint discovery or translational projects.
Expertise Areas
- Repeat biology and 'dark genome' therapeutics
- Structure-based small-molecule drug discovery
- Data-science-driven target discovery for noncoding genomic elements
- Machine learning for genomic expression quantification
Key Technologies
- Next-generation sequencing (NGS)
- Machine learning for expression quantification
- High-resolution structural biology (X-ray crystallography)
- Structure-based drug design